MetaCap

Context Therapeutics Inc. (CNTX)

NASDAQ: CNTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.16-0.0086 (-5.10%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

CNTX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$14.70M
EPS (TTM)
-$0.46
52-week range
0.153 – 3.62
Day range
0.1575 – 0.1754
Volume / Avg
1.11M / 1.42M
Beta
—

52-week range

$0.153$3.62

CNTX stock today

Context Therapeutics (CNTX) closed at $0.16 on Nov 20, down 5.10% (-$0.0086), versus the S&P 500's 3.70% decline. Shares are 95.6% below their 52-week high of $3.62, set on Mar 16, 2026 and 4.6% above the 52-week low of $0.153, near the bottom of the past year's range. CNTX is down 89.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 85.3%.

Context Therapeutics has posted a net loss over the last twelve months (EPS of -$0.46), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Context Therapeutics

Company profile

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Martin A. Lehr
Headquarters
Philadelphia, PA
Employees
15
IPO year
2021

Financial highlights

Full financials

Context Therapeutics reported a net loss of $36.1 million, compared with a loss of $26.7 million a year earlier. Diluted earnings per share came in at -$0.38.

Context Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-36.12M$-26.73M$-23.96M$-14.84M$-10.46M
EPS (diluted)$-0.38$-0.46$-1.50$-0.93$-3.69

Analyst forecast

Forecast

Consensus (10 analysts)

none

Avg. price target

$4.03+2418.75%

  • Strong buy 3
  • Buy 6
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $2.00High $5.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 10, 2026
EPS actual vs est.
$-0.08 vs $-0.09
Surprise
+11.11%

CNTX news

All CNTX news

Context Therapeutics peers

Health Care sector
CNTX peer companies
CompanyPrice% ChgMarket capCompare
NCELNewcelX Ltd.2.54-5.58%$14.67Mvs CNTX
CELUCelularity Inc. Class A0.463-1.05%$15.02Mvs CNTX
CTXRCitius Pharmaceuticals Inc.0.5085+2.27%$13.96Mvs CNTX
BYSIBeyondSpring Inc.0.33-24.49%$13.66Mvs CNTX
QNRXQuoin Pharmaceuticals Ltd. ADR3.28-2.35%$15.76Mvs CNTX
PBMPsyence Biomedical Ltd.2.97+3.85%$15.80Mvs CNTX
ACTUActuate Therapeutics Inc.0.2253+5.38%$13.60Mvs CNTX
ATOSAtossa Therapeutics Inc.1.60-8.86%$15.92Mvs CNTX

Indexes, lists and sector

Context Therapeutics stock FAQ

What is Context Therapeutics's stock price today?

CNTX last traded at $0.16 as of Nov 20, 4:00 PM EST, down 5.10% on the day. Prices are delayed at least 15 minutes.

Who is Context Therapeutics's CEO?

Mr. Martin A. Lehr is the chief executive officer of Context Therapeutics Inc., which has about 15 employees.

What is the CNTX 52-week high?

The 52-week high for CNTX is $3.62 and the 52-week low is $0.153. The stock is currently 95.6% below its high.

Compare CNTX